The global induced pluripotent stem cells market value stood at USD 1.73 billion in 2023 and it is predicted to rise to USD 4.58 billion by 2033 with solid CAGR of 24.5% from 2024 to 2033.
The market for stem cell-based therapies is experiencing significant growth due to several key factors: the potential of these therapies, the rising incidence of cancer, increased capital investments in stem cell research, and the advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs). According to the American Cancer Society, approximately 1.9 million new cancer cases and around 609,820 cancer-related deaths are expected in the U.S. in 2023.
The COVID-19 pandemic has also spurred increased research activity involving iPSCs. Scientists’ ongoing efforts to develop new treatments for SARS-CoV-2 infection have heightened the demand for iPSCs as valuable research tools. iPSCs’ ability to generate organ models or organoids that mimic human physiology makes them essential for studying the virus’s impact.
The growth of iPSCs-based research is further accelerated by the large number of ongoing clinical trials. Over 120 trials are currently exploring the use of iPSCs for disease intervention and product development. The advantages of iPSCs, such as reducing the need for animal models and avoiding the ethical issues associated with ESCs, contribute to the expanding market. This favorable environment has attracted numerous businesses to explore iPSCs for applications such as drug discovery, disease modeling, and toxicological testing. For example, in August 2021, Fate Therapeutics announced that FT819, an iPSC-derived engineered CAR-T cell therapy, successfully treated its first patient in a clinical trial.
Key Insights:
- North America led the global induced pluripotent stem cells (iPSCs) market with a dominant share of 37% in 2023.
- The Asia Pacific region is projected to grow at the highest CAGR of 12.34% from 2024 to 2033.
- Among derived cell types, fibroblasts held the largest market share of 31% in 2023.
- The hepatocytes segment is expected to experience the fastest CAGR of 12.93% from 2024 to 2033.
- In terms of application, drug development captured the largest market share of 50% in 2023.
- The tissue engineering and regenerative medicine segment is anticipated to grow at a significant CAGR of 11.93% from 2024 to 2033.
- Pharmaceutical and biotechnology companies held the largest market share of 60% by end-use in 2023.
- The academic and research institutes segment is expected to grow at the fastest CAGR of 10.94% from 2024 to 2033.
Get Sample@ https://www.visionresearchreports.com/report/sample/41569
Understanding Induced Pluripotent Stem Cells
What Are Induced Pluripotent Stem Cells?
Induced pluripotent stem cells are adult cells that have been genetically reprogrammed to acquire properties similar to embryonic stem cells. These cells have the capability to differentiate into nearly any cell type in the body, making them invaluable for a range of applications from disease modeling to regenerative therapy.
How Are iPSCs Created?
The process of creating iPSCs involves the introduction of specific transcription factors into somatic cells. These factors reprogram the cells by activating the pluripotency genes. The most commonly used factors include Oct4, Sox2, Klf4, and c-Myc, known collectively as the Yamanaka factors.
Applications of Induced Pluripotent Stem Cells
Disease Modeling
iPSCs are extensively used to create disease models that mimic human disease states. These models help researchers understand disease mechanisms and evaluate the efficacy of new treatments. Notable applications include:
- Neurodegenerative Diseases: iPSCs are used to model diseases such as Alzheimer’s and Parkinson’s.
- Cardiovascular Diseases: Researchers use iPSCs to study heart diseases and develop potential treatments.
Drug Development and Testing
Pharmaceutical companies are leveraging iPSCs to develop and test new drugs. By using iPSC-derived cell types, researchers can assess drug effects and safety in a more relevant biological context, potentially reducing the time and cost of drug development.
Regenerative Medicine
iPSCs hold promise for regenerative medicine, including tissue and organ replacement. Potential applications include:
- Tissue Engineering: Creating tissues for transplantation or repairing damaged tissues.
- Organ Replacement: Developing functional organs for transplant, although this application is still largely experimental.
Future Trends in the Induced Pluripotent Stem Cells (iPSCs) Market
- Advanced Disease Modeling:
- Emerging Trend: Increased use of iPSCs for creating more accurate disease models that replicate human disease conditions more closely than traditional models.
- Impact: Enhanced ability to understand disease mechanisms, identify new drug targets, and develop personalized treatment plans.
- Regenerative Medicine and Tissue Engineering:
- Emerging Trend: Growth in developing advanced regenerative therapies and tissue engineering applications, including organ and tissue replacement using iPSCs.
- Impact: Potential to address organ shortages and repair damaged tissues with personalized, patient-specific treatments.
- Integration with Genomic Technologies:
- Emerging Trend: Integration of iPSCs with CRISPR and other genomic editing technologies to create genetically modified cells for research and therapy.
- Impact: Improved precision in genetic research and development of new treatments for genetic disorders and complex diseases.
- Expansion in Clinical Applications:
- Emerging Trend: Increasing clinical trials and applications of iPSCs in regenerative medicine, cancer immunotherapy, and rare genetic diseases.
- Impact: Greater clinical validation and adoption of iPSC-based therapies, expanding treatment options for patients with currently untreatable conditions.
- Personalized Medicine:
- Emerging Trend: Growing emphasis on personalized medicine approaches using iPSCs to tailor treatments based on individual genetic profiles and disease characteristics.
- Impact: Enhanced efficacy and reduced side effects of treatments by aligning them more closely with individual patient needs.
- Commercialization and Market Expansion:
- Emerging Trend: Increased investment and commercialization of iPSC technologies, leading to a broader range of products and services, including cell-based assays and diagnostic tools.
- Impact: Expansion of market opportunities and accessibility of iPSC technologies across various industries, including pharmaceuticals, biotechnology, and healthcare.
Induced Pluripotent Stem Cells Market Recent Developments
- In September 2023, Ushio, Inc. partnered with Axol Bioscience to source iPSC-derived sensory neuron cells. This collaboration enabled Ushio to integrate human iPSC-derived axoCells sensory neurons into its in vitro Nerve Plate platform.
- In February 2023, Lineage Cell Therapeutics, Inc. teamed up with Eterna Therapeutics, Inc. to develop beta 2 microglobulin (B2M)-deficient iPSC lines. These new cell lines, developed by Eterna, are set to enhance Lineage’s product offerings for treating specific central nervous system (CNS) disorders and other neurological conditions.
- In January 2022, Bristol-Myers Squibb Company established a strategic partnership with Century Therapeutics to advance iPSC-derived allogeneic cell therapy. This collaboration was anticipated to strengthen Bristol-Myers Squibb’s portfolio in stem cell-based therapies.
Top Manufacturers in the Induced Pluripotent Stem Cells (iPSCs) Market
1. STEMCELL Technologies Inc.
- Demand: STEMCELL Technologies is a leading provider of specialized cell culture media, reagents, and tools for iPSC research and applications.
- Recent Developments: The company recently expanded its product line with advanced iPSC culture media and differentiation kits. They are actively involved in developing innovative solutions to support iPSC research and clinical applications.
- Investment: STEMCELL Technologies has significantly invested in R&D to enhance its product offerings and support the growing demand for iPSC-based technologies.
2. Cellular Engineering Technologies Inc.
- Demand: Known for its expertise in cell therapy and regenerative medicine, Cellular Engineering Technologies focuses on developing iPSC-based products for various therapeutic applications.
- Recent Developments: The company has been advancing its iPSC-derived cell therapies and expanding its portfolio with new research tools and cell-based assays.
- Investment: The company continues to invest in R&D to drive innovation and advance its iPSC technology capabilities.
3. REPROCELL Inc.
- Demand: REPROCELL provides a wide range of iPSC-related products, including cell lines, culture systems, and differentiation kits for drug discovery and regenerative medicine.
- Recent Developments: REPROCELL has been expanding its iPSC-based product offerings and has entered into partnerships to develop new therapies and technologies.
- Investment: The company invests heavily in R&D and strategic collaborations to enhance its iPSC product portfolio and market presence.
4. Takara Bio, Inc.
- Demand: Takara Bio is a prominent player in the iPSC market, offering a variety of tools for iPSC research, including cell culture systems, gene editing technologies, and differentiation kits.
- Recent Developments: Takara Bio has been expanding its product range with advanced iPSC culture and analysis tools, and it continues to advance its R&D in regenerative medicine.
- Investment: The company allocates substantial resources to R&D to support innovation and improve its iPSC-related products.
5. Axol Bioscience Ltd.
- Demand: Axol Bioscience specializes in providing high-quality iPSC-derived cell products and reagents for drug discovery and disease modeling.
- Recent Developments: Axol has been enhancing its iPSC-derived cell offerings and developing new products to support research in neurodegenerative diseases and other therapeutic areas.
- Investment: Axol invests in expanding its product range and developing new technologies to meet the growing demand for iPSC-based research tools.
6. Fate Therapeutics, Inc.
- Demand: Fate Therapeutics is known for its development of iPSC-derived cell therapies, including engineered CAR-T cells for cancer treatment.
- Recent Developments: The company made headlines with the successful clinical trial of its iPSC-derived CAR-T cell therapy, FT819. They continue to advance their iPSC-based therapeutic pipeline.
- Investment: Fate Therapeutics invests heavily in R&D to further develop its iPSC-based therapies and expand its clinical trials.
Read More@ https://www.heathcareinsights.com/breast-adenocarcinoma-treatment-market/
Induced Pluripotent Stem Cells Market Segmentation:
By Derived Cell Type
- Hepatocytes
- Fibroblasts
- Keratinocytes
- Amniotic Cells
- Others
By Application
- Drug Development
- Tissue Engineering & Regenerative Medicine
- Neurology
- Orthopedics
- Oncology
- Cardiovascular and Myocardial Infraction
- Diabetes
- Others
- Toxicology Research
- Disease Modeling
By End-use
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41569
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308